Lilly's Lebrikizumab shows improved face or hand dermatitis

Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients

Aarti Drugs reports Q4 FY23 PAT at Rs.56.02 Cr

Specialty Chemicals grew 38% YoY for FY23

Biocon Biologics' new mAbs facility receives EU GMP Certification for bBevacizumab

This approval reflects Biocon Biologics' compliance with the highest international regulatory standards

PI Industries announces twin acquisitions into Pharma API & CDMO space

Biocon approves NCD issue

The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.

Syngene International posts Q4 FY2023 consolidated profit at Rs. 178.7 Cr

The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023

Venus Remedies secures marketing authorization from UK MHRA for Cisplatin

Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country

Aster RV Hospital launch needleless injections in South India

A special technique of jet injection is used to make vaccination almost painless and totally needleless.

Huge milestones made towards Zero Malaria goal, says GlobalData

Malaria is a life-threatening parasitic infection that is spread by the bites of mosquitoes carrying the Plasmodium parasite

USFDA lifts clinical hold on Phase 3 investigational new drug application for MaaT013

This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology